US5254539A
(en)
*
|
1985-08-26 |
1993-10-19 |
U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health |
Method of treating HIV with 2',3'-dideoxyinosine
|
US5204113A
(en)
*
|
1987-04-09 |
1993-04-20 |
Fisons Plc |
Pharmaceutical compositions containing pentamidine
|
DE3872635T2
(de)
*
|
1987-04-09 |
1992-12-17 |
Fisons Plc |
Pentamidin enthaltende pharmazeutische zusammensetzungen.
|
JPH02204489A
(ja)
*
|
1989-02-02 |
1990-08-14 |
Ajinomoto Co Inc |
易溶性2’,3’―ジデオキシイノシン、その製造法及び2’,3’―ジデオキシイノシン水性溶液の製造法
|
SE464168B
(sv)
*
|
1989-07-19 |
1991-03-18 |
Bo Fredrik Oeberg |
Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
|
US5026687A
(en)
*
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
US5162361A
(en)
*
|
1990-04-10 |
1992-11-10 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Method of treating diseases associated with elevated levels of interleukin 1
|
HU9202318D0
(en)
*
|
1991-07-22 |
1992-10-28 |
Bristol Myers Squibb Co |
Method for preparing medical preparatives containing didesoxi-purine nucleoside
|
US5231174A
(en)
*
|
1992-02-27 |
1993-07-27 |
University Of Iowa Research Foundation |
2'isodideoxy-β-D-nucleosides as stable antiviral agents
|
US5419900A
(en)
|
1993-05-19 |
1995-05-30 |
The United States Of America As Represented By The Department Of Of Health And Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
US5696079A
(en)
*
|
1993-05-19 |
1997-12-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
ATE273700T1
(de)
*
|
1993-05-21 |
2004-09-15 |
Us Gov Health & Human Serv |
Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
|
EP0631783A1
(en)
*
|
1993-06-03 |
1995-01-04 |
Mitsubishi Chemical Corporation |
Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
|
US6093702A
(en)
*
|
1993-12-20 |
2000-07-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
|
US5521161A
(en)
*
|
1993-12-20 |
1996-05-28 |
Compagnie De Developpment Aguettant S.A. |
Method of treating HIV in humans by administration of ddI and hydroxycarbamide
|
US6130036A
(en)
*
|
1994-02-18 |
2000-10-10 |
University Of Washington |
Methods and compositions for screening for anti-AIDS drugs
|
US6338963B1
(en)
|
1994-07-25 |
2002-01-15 |
Neotherapeutics, Inc. |
Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
|
EP1852121A3
(en)
|
1994-08-29 |
2007-11-21 |
Wake Forest University |
Lipid analogs for treating viral infections
|
US7135584B2
(en)
*
|
1995-08-07 |
2006-11-14 |
Wake Forest University |
Lipid analogs for treating viral infections
|
US20020058636A1
(en)
*
|
1994-09-21 |
2002-05-16 |
Geoffrey P. Symonds |
Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
|
US20030180254A1
(en)
*
|
1995-05-26 |
2003-09-25 |
The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
US5840711A
(en)
*
|
1995-06-21 |
1998-11-24 |
University Of Kentucky Research Foundation |
Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
|
CA2329474C
(en)
|
1995-11-02 |
2002-02-26 |
Schering Corporation |
Continuous low-dose cytokine infusion therapy
|
US6509313B1
(en)
|
1996-02-28 |
2003-01-21 |
Cornell Research Foundation, Inc. |
Stimulation of immune response with low doses of cytokines
|
US6528098B2
(en)
*
|
1996-10-22 |
2003-03-04 |
Advanced Viral Research Corp. |
Preparation of a therapeutic composition
|
US20030100532A1
(en)
*
|
1997-02-14 |
2003-05-29 |
Gary S. Jacob |
Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
|
US6114312A
(en)
*
|
1997-03-07 |
2000-09-05 |
Research Institute For Genetic And Human Therapy (R.I.G.H.T.) |
Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
|
KR100220645B1
(ko)
*
|
1997-07-04 |
1999-09-15 |
구광시 |
벤젠유도체의 제조방법
|
US6800616B2
(en)
*
|
1998-02-26 |
2004-10-05 |
Supergen, Inc. |
Treatment of HIV infections
|
AU3786299A
(en)
|
1998-05-04 |
1999-11-23 |
Neotherapeutics, Inc. |
Novel serotonin-like 9-substituted hypoxanthine and methods of use
|
WO2000016625A1
(en)
*
|
1998-09-23 |
2000-03-30 |
University Of Kentucky Research Foundation |
Antiviral drug compositions containing lithium inorganic salts
|
WO2001012228A2
(en)
|
1999-08-13 |
2001-02-22 |
University Of Maryland Biotechnology Institute |
Compositions for treating viral infections, and methods therefor
|
US7026469B2
(en)
*
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
US6288069B1
(en)
|
1999-11-16 |
2001-09-11 |
Neotherapeutics, Inc. |
Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
|
US6407237B1
(en)
|
2001-02-21 |
2002-06-18 |
Neotherapeutics, Inc. |
Crystal forms of 9-substituted hypoxanthine derivatives
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
US6849735B1
(en)
|
2000-06-23 |
2005-02-01 |
Merck Eprova Ag |
Methods of synthesis for 9-substituted hypoxanthine derivatives
|
ATE499103T1
(de)
|
2000-07-07 |
2011-03-15 |
Spectrum Pharmaceuticals Inc |
Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen
|
PT1411954E
(pt)
|
2000-10-18 |
2011-03-16 |
Pharmasset Inc |
Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
|
US7309696B2
(en)
|
2000-10-19 |
2007-12-18 |
Wake Forest University |
Compositions and methods for targeting cancer cells
|
WO2002048165A2
(en)
*
|
2000-12-15 |
2002-06-20 |
Pharmasset Ltd. |
Antiviral agents for treatment of flaviviridae infections
|
US6759427B2
(en)
|
2001-04-20 |
2004-07-06 |
Spectrum Pharmaceuticals, Inc. |
Synthesis and methods of use of tetrahydroindolone analogues and derivatives
|
WO2002096826A2
(en)
*
|
2001-05-29 |
2002-12-05 |
Koninklijke Philips Electronics N.V. |
Metal-ceramic bond
|
ES2358187T3
(es)
*
|
2001-07-10 |
2011-05-06 |
JOHNSON & JOHNSON RESEARCH PTY LIMITED |
Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
|
US20030055249A1
(en)
*
|
2001-07-17 |
2003-03-20 |
Fick David B. |
Synthesis and methods of use of pyrimidine analogues and derivatives
|
JP4714413B2
(ja)
*
|
2001-08-31 |
2011-06-29 |
トムソン ライセンシング |
オーディオビジュアルストリームのためのシーケンスカウンタ
|
JP2005504087A
(ja)
*
|
2001-09-28 |
2005-02-10 |
イデニクス(ケイマン)リミテツド |
4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物
|
KR20040094692A
(ko)
*
|
2002-02-14 |
2004-11-10 |
파마셋, 리미티드 |
변형된 불소화 뉴클레오사이드 유사체
|
EP2799442A1
(en)
|
2002-06-28 |
2014-11-05 |
IDENIX Pharmaceuticals, Inc. |
Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
|
BR0313164A
(pt)
*
|
2002-08-01 |
2007-07-17 |
Pharmasset Inc |
compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
ES2586668T3
(es)
|
2003-05-30 |
2016-10-18 |
Gilead Pharmasset Llc |
Análogos de nucleósidos fluorados modificados
|
AU2004258750A1
(en)
*
|
2003-07-25 |
2005-02-03 |
Centre National De La Recherche Scientifique -Cnrs |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
US20050187192A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Pharmaceutical Company |
Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
|
US20050187191A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Louis S. |
Methods and compositions for the treatment of respiratory syncytial virus
|
US20060040944A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
MX2007003085A
(es)
*
|
2004-09-14 |
2007-08-02 |
Pharmasset Inc |
Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
|
AU2005332686B2
(en)
*
|
2005-06-03 |
2012-09-27 |
Ohr Pharmaceutical, Inc. |
Methods for providing palliative care with AVR118
|
NZ571826A
(en)
|
2006-04-11 |
2012-01-12 |
Novartis Ag |
HCV/HIV inhibitors and their uses
|
EP2068906B1
(en)
|
2006-09-19 |
2012-08-01 |
Sungkyunkwan University Foundation for Corporate Collaboration |
Antiviral agent against animal viruses
|
AU2008219622A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
EP2376514A2
(en)
*
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
MX2011006891A
(es)
*
|
2008-12-23 |
2011-10-06 |
Pharmasset Inc |
Fosforamidatos de nucleosidos.
|
EP2403860B1
(en)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
CN102822175A
(zh)
|
2009-12-18 |
2012-12-12 |
埃迪尼克斯医药公司 |
5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
|
AU2011235112B2
(en)
|
2010-03-31 |
2015-07-09 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
MX2012011222A
(es)
|
2010-04-01 |
2013-01-18 |
Centre Nat Rech Scient |
Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
|
MX2013003945A
(es)
|
2010-10-08 |
2013-06-05 |
Novartis Ag |
Formulaciones de vitamina e como inhibidoras de sulfamida ns3.
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
WO2012107584A1
(en)
|
2011-02-11 |
2012-08-16 |
Universite Pierre Et Marie Curie (Paris 6) |
Methods for predicting outcome of a hepatitis virus infection
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2843495A1
(en)
|
2011-08-03 |
2013-02-07 |
Cytheris |
Hcv immunotherapy
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
NZ623396A
(en)
|
2011-09-16 |
2016-07-29 |
Gilead Pharmasset Llc |
Methods for treating hcv
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
|
AU2013201532B2
(en)
|
2011-10-21 |
2014-10-02 |
Abbvie Ireland Unlimited Company |
Methods for treating HCV
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
CH707029B1
(de)
|
2011-10-21 |
2015-03-13 |
Abbvie Inc |
Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
CN104185420B
(zh)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
AU2013266393B2
(en)
|
2012-05-22 |
2017-09-28 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
GEP201706723B
(en)
|
2012-10-08 |
2017-08-25 |
Idenix Pharmaceuticals Llk |
2'-chloro nucleoside analogs for hcv infection
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
LT2950786T
(lt)
|
2013-01-31 |
2020-03-10 |
Gilead Pharmasset Llc |
Dviejų antivirusinių junginių preparatų kompozicija
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
NZ716840A
(en)
|
2013-08-27 |
2017-06-30 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
EP3114122A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
WO2015134561A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
US11192914B2
(en)
|
2016-04-28 |
2021-12-07 |
Emory University |
Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
|
EP3927710A4
(en)
*
|
2019-03-08 |
2022-12-21 |
University of Virginia Patent Foundation |
COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE
|